Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJayastu SenapatiSLSanam LoghaviÁBÁlex Bataller

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows first-line therapy improves response rates in older patients with aplastic anemia, highlighting the role of eltrombopag.

Key Points

  • Assess the effectiveness of ATG-based immunosuppressive therapy in older patients with aplastic anemia.
  • Retrospective analysis of patients aged ≥60 years receiving ATG-based therapy.
  • Comparison of outcomes between patients aged 60-69 and ≥70 years.
  • Evaluation of disease severity and response rates using clinical measures.
  • Overall response rate was 59%, with median overall survival of 55.6 months.
  • Patients ≥70 years had significantly lower response rates compared to those <70 years.
  • The addition of eltrombopag was significantly associated with improved response rates.

Cite This Study

Senapati et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5c3https://doi.org/10.1182/blood-2025-3206
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Aplastic anemia treatment in older adults in resource-limited settings: Can rabbit ATG bridge the gap?2025
  2. 2Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry2026
  3. 3Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia2024 · 12 citations
  4. 4Thrombopoietin receptor agonists combined with intensive immunosuppressive therapy improve outcomes in elderly patients with severe aplastic anemia: A single-center retrospective study2025
  5. 5Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies2025